Janesville, WI – On January 16th SHINE Medical Technologies, Inc. (SHINE), a company dedicated to being the world leader in the safe, clean, affordable production of medical isotopes, held a ribbon cutting ceremony to celebrate the grand opening of the company’s new global headquarters in downtown Janesville, Wisconsin. The ribbon cutting was led by the John Beckord and the Forward Janesville Goodwill Ambassadors.
SHINE employees were joined at the celebration by neighbors and Janesville community members. Flora Csontos spoke on behalf of Senator Tammy Baldwin, congratulating SHINE. In honor of the Martin Luther King, Jr. Day of Service, guests of the ceremony were asked to bring a non-perishable food item to benefit ECHO (Everyone Cooperating to Help Others). A full barrel of donations was collected for the local food pantry.
Approximately 35 SHINE employees now occupy the top floor of the Prospect 101 building at 101 E. Milwaukee Street. SHINE employees will continue operations in the new headquarters while the company prepares for construction of its medical radioisotope production facility, which was approved by the U.S. Nuclear Regulatory Commission last February. The building is approximately 6 miles north of the future production facility, which will be built near the Southern Wisconsin Regional Airport. SHINE is expected to grow to 60+ employees in 2017, and employ 150 people at its future production facility.
SHINE selected Janesville for the location of its production facility after an extensive site selection process in 2012.
Molybdenum-99 (moly-99) is a radioisotope that decays into the diagnostic imaging agent technetium‑99m (Tc-99m). Tc-99m is used in more than 40 million medical imaging procedures each year, primarily in stress tests to diagnose heart disease and bone scans to stage cancer. SHINE was founded to deploy a safe, cost-effective and environmentally friendly technology to produce medical isotopes, including moly‑99.
About SHINE Medical Technologies, Inc.
Founded in 2010, SHINE is a development-stage company working toward becoming a manufacturer of radioisotopes for nuclear medicine. The SHINE system uses a patented, proprietary manufacturing process that offers major advantages over existing and proposed production technologies as it does not require a nuclear reactor, uses less electricity, generates less waste and is compatible with the nation’s existing supply chain for molybdenum-99. In 2014, SHINE announced the execution of molybdenum-99 supply agreements with GE Healthcare and Lantheus Medical Imaging. In 2015, with the help of Argonne National Laboratory, GE Healthcare demonstrated SHINE molybdenum-99 can act as a drop-in replacement for reactor-based moly-99. In June of 2016, SHINE signed a moly-99 supply agreement with HTA Co., Ltd. (HTA), the largest Chinese producer and distributor of radio-pharmaceuticals. Learn more at http://shinemed.com.